• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Sieve analysis using the number of infecting pathogens.使用感染病原体数量进行筛分分析。
Biometrics. 2018 Sep;74(3):1023-1033. doi: 10.1111/biom.12833. Epub 2017 Dec 14.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Incorporating founder virus information in vaccine field trials.将原始病毒信息纳入疫苗现场试验。
Biometrics. 2015 Jun;71(2):386-96. doi: 10.1111/biom.12277. Epub 2015 Mar 13.
4
Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.筛析:从疫苗试验数据评估疫苗效力如何随基因型和表型病原体变异而变化的方法。
J Clin Epidemiol. 2001 Jan;54(1):68-85. doi: 10.1016/s0895-4356(00)00258-4.
5
Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.比较用于评估疫苗保护中应变变异的竞争风险失败时间方法和与时间无关的方法。
Stat Med. 2000 Nov 30;19(22):3065-86. doi: 10.1002/1097-0258(20001130)19:22<3065::aid-sim600>3.0.co;2-d.
6
Assessing trends in vaccine efficacy by pathogen genetic distance.通过病原体遗传距离评估疫苗效力的趋势。
J Soc Fr Statistique (2009). 2020 Jul;161(1):164-175.
7
Vaccine approaches to malaria control and elimination: Insights from mathematical models.疟疾控制与消除的疫苗策略:数学模型的见解
Vaccine. 2015 Dec 22;33(52):7544-50. doi: 10.1016/j.vaccine.2015.09.099. Epub 2015 Oct 23.
8
Estimating and Testing Vaccine Sieve Effects Using Machine Learning.使用机器学习估计和测试疫苗筛选效果
J Am Stat Assoc. 2019;114(527):1038-1049. doi: 10.1080/01621459.2018.1529594. Epub 2019 Apr 3.
9
[Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].[单供体(单采)血小板与混合全血来源血小板——两种血液制品的意义及评估]
Clin Lab. 2014;60(4):S1-39. doi: 10.7754/clin.lab.2014.140210.
10
Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials.疟疾暴露和疫苗反应的异质性:对疫苗效力试验解释的影响。
Malar J. 2010 Mar 23;9:82. doi: 10.1186/1475-2875-9-82.

引用本文的文献

1
Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?将基因分型数据纳入疗效估算器能否提高疟疾疫苗早期临床试验的效率?
Malar J. 2023 Dec 19;22(1):383. doi: 10.1186/s12936-023-04802-0.
2
Impacts of Ecology, Parasite Antigenic Variation, and Human Genetics on RTS,S/AS01e Malaria Vaccine Efficacy.生态、寄生虫抗原变异和人类遗传学对RTS,S/AS01e疟疾疫苗效力的影响
Curr Epidemiol Rep. 2021;8(3):79-88. doi: 10.1007/s40471-021-00271-8. Epub 2021 Jul 30.

本文引用的文献

1
Mark-specific hazard ratio model with missing multivariate marks.具有缺失多变量标记的特定标记风险比模型。
Lifetime Data Anal. 2016 Oct;22(4):606-25. doi: 10.1007/s10985-015-9353-9. Epub 2015 Oct 28.
2
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.RTS,S/AS01疟疾疫苗的遗传多样性与保护效力
N Engl J Med. 2015 Nov 19;373(21):2025-2037. doi: 10.1056/NEJMoa1505819. Epub 2015 Oct 21.
3
Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.RTS,S/AS疟疾疫苗的临床开发:对I-III期临床试验的系统评价
Future Microbiol. 2015;10(10):1553-78. doi: 10.2217/fmb.15.90. Epub 2015 Oct 6.
4
Incorporating founder virus information in vaccine field trials.将原始病毒信息纳入疫苗现场试验。
Biometrics. 2015 Jun;71(2):386-96. doi: 10.1111/biom.12277. Epub 2015 Mar 13.
5
Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.具有多变量连续标记的标记特异性风险比模型:在疫苗效力中的应用
Biometrics. 2013 Jun;69(2):328-37. doi: 10.1111/biom.12016. Epub 2013 Feb 19.
6
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.RTS,S/AS01 疟疾疫苗在非洲婴儿中的 3 期临床试验。
N Engl J Med. 2012 Dec 13;367(24):2284-95. doi: 10.1056/NEJMoa1208394. Epub 2012 Nov 9.
7
Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.带有多元连续标记的标记特异性比例风险模型及其在 HIV 疫苗功效试验中的应用。
Biostatistics. 2013 Jan;14(1):60-74. doi: 10.1093/biostatistics/kxs022. Epub 2012 Jul 3.
8
Unexpected fold in the circumsporozoite protein target of malaria vaccines.疟疾疫苗的环子孢子蛋白靶标出现意外折叠。
Proc Natl Acad Sci U S A. 2012 May 15;109(20):7817-22. doi: 10.1073/pnas.1205737109. Epub 2012 Apr 30.
9
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.原发性HIV-1感染中传播及早期奠基者病毒包膜的鉴定与特征分析
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7. doi: 10.1073/pnas.0802203105. Epub 2008 May 19.
10
Multiple outputation: inference for complex clustered data by averaging analyses from independent data.多重输出:通过对独立数据的分析求平均值来推断复杂聚类数据。
Biometrics. 2003 Jun;59(2):420-9. doi: 10.1111/1541-0420.00049.

使用感染病原体数量进行筛分分析。

Sieve analysis using the number of infecting pathogens.

作者信息

Follmann Dean, Huang Chiung-Yu

机构信息

Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Bethesda, Maryland 20892, U.S.A.

Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 550 N. Broadway, Baltimore, Maryland 21205, U.S.A.

出版信息

Biometrics. 2018 Sep;74(3):1023-1033. doi: 10.1111/biom.12833. Epub 2017 Dec 14.

DOI:10.1111/biom.12833
PMID:29238965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6004265/
Abstract

Assessment of vaccine efficacy as a function of the similarity of the infecting pathogen to the vaccine is an important scientific goal. Characterization of pathogen strains for which vaccine efficacy is low can increase understanding of the vaccine's mechanism of action and offer targets for vaccine improvement. Traditional sieve analysis estimates differential vaccine efficacy using a single identifiable pathogen for each subject. The similarity between this single entity and the vaccine immunogen is quantified, for example, by exact match or number of mismatched amino acids. With new technology, we can now obtain the actual count of genetically distinct pathogens that infect an individual. Let F be the number of distinct features of a species of pathogen. We assume a log-linear model for the expected number of infecting pathogens with feature "f," . The model can be used directly in studies with passive surveillance of infections where the count of each type of pathogen is recorded at the end of some interval, or active surveillance where the time of infection is known. For active surveillance, we additionally assume that a proportional intensity model applies to the time of potentially infectious exposures and derive product and weighted estimating equation (WEE) estimators for the regression parameters in the log-linear model. The WEE estimator explicitly allows for waning vaccine efficacy and time-varying distributions of pathogens. We give conditions where sieve parameters have a per-exposure interpretation under passive surveillance. We evaluate the methods by simulation and analyze a phase III trial of a malaria vaccine.

摘要

评估疫苗效力与感染病原体和疫苗的相似性之间的关系是一个重要的科学目标。对疫苗效力较低的病原体菌株进行特征描述,可以增进对疫苗作用机制的理解,并为疫苗改进提供靶点。传统的筛选分析使用每个受试者单一可识别的病原体来估计疫苗效力差异。例如,通过精确匹配或错配氨基酸的数量来量化这个单一实体与疫苗免疫原之间的相似性。借助新技术,我们现在能够获取感染个体的基因不同病原体的实际数量。设F为一种病原体的不同特征数量。我们对具有特征“f”的感染病原体的预期数量假定一个对数线性模型 。该模型可直接用于对感染进行被动监测的研究,即在某个时间段结束时记录每种病原体的数量,或者用于主动监测,即已知感染时间的情况。对于主动监测,我们还假定比例强度模型适用于潜在感染暴露的时间,并推导对数线性模型中回归参数的乘积和加权估计方程(WEE)估计量。WEE估计量明确考虑了疫苗效力的减弱和病原体的时变分布。我们给出了在被动监测下筛选参数具有每次暴露解释的条件。我们通过模拟评估这些方法,并分析一项疟疾疫苗的III期试验。